The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors

Table 4

The role of RDCI and other baseline factors as predictors of TNFi persistence.

	HR	95CI	P
Age, years	1.005	0.990-1.019	0.523
Sex	1.090	0.684-1.738	0.716
Disease duration, years	0.999	0.979-1.018	0.897
DAS28-ESR	1.122	0.934-1.348	0.218
HAQ	0.926	0.608-1.410	0.721
RF	1.198	0.796-1.803	0.386
Concomitant MTX	0.622	0.440-0.877	0.007
bDMARD (ETN vs ADA)	0.493	0.343-0.707	<0.001
RDCI	1.186	1.011-1.390	0.036

HR: hazard ratio; CI: confidence intervals; DAS28-ESR: disease activity score 28- erythrocyte sedimentation rate; HAQ: health assessment questionnaire; RF: rheumatoid factor; MTX: methotrexate; bDMARD: biologic disease modifying anti-rheumatic drugs; ETN: etanercept; ADA: adalimumab; RDCI: rheumatic disease comorbidity index.